LETROZOLE DENK is a potent aromatase inhibitor widely prescribed for the treatment of hormone receptor-positive breast cancer in postmenopausal women. This 2.5MG tablet works by significantly reducing estrogen levels in the body, thereby slowing or stopping the growth of cancer cells that rely on estrogen to proliferate. Approved by regulatory authorities, LETROZOLE DENK is a cornerstone in adjuvant and metastatic breast cancer therapy, offering patients a well-tolerated and effective treatment option with a proven track record in clinical trials.